Research programme: influenza vaccines - MedImmune/Novartis
Latest Information Update: 15 Aug 2011
At a glance
- Originator Novartis
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 15 Aug 2011 Discontinued for Influenza virus infections in Switzerland (unspecified route)